Boule Diagnostics AB Reports Earnings Results for the Full Year Ended December 31, 2021
February 03, 2022 at 02:30 am EST
Share
Boule Diagnostics AB (publ) reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was SEK 463.3 million compared to SEK 400.5 million a year ago. Net income was SEK 23.3 million compared to net loss of SEK 48 million a year ago.
Basic earnings per share from continuing operations was SEK 1.2 compared to basic loss per share from continuing operations of SEK 2.47 a year ago. Diluted earnings per share from continuing operations was SEK 1.17.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
